Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 963568, 6 pages
http://dx.doi.org/10.1155/2015/963568
Research Article

Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus

1Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital, Xiamen University, No. 55, Zhenhai Road, Xiamen 361003, China
2Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA

Received 25 August 2014; Accepted 24 November 2014

Academic Editor: Xuan Zhang

Copyright © 2015 Yuan Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Satoh, E. K. L. Chan, E. S. Sobel et al., “Clinical implication of autoantibodies in patients with systemic rheumatic diseases,” Expert Review of Clinical Immunology, vol. 3, no. 5, pp. 721–738, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. M. Tan, “Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology,” Advances in Immunology, vol. 44, pp. 93–151, 1989. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. Yamasaki, S. Narain, H. Yoshida et al., “Autoantibodies to RNA helicase A: a new serologic marker of early lupus,” Arthritis and Rheumatism, vol. 56, no. 2, pp. 596–604, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. E. M. Tan, J. S. Smolen, J. S. McDougal et al., “A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity,” Arthritis and Rheumatism, vol. 42, no. 3, pp. 455–464, 1999. View at Google Scholar
  5. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, “Mdm2 promotes the rapid degradation of p53,” Nature, vol. 387, no. 6630, pp. 296–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. E. Forte and M. A. Luftig, “MDM2-dependent inhibition of p53 is required for epstein-barr virus B-cell growth transformation and infected-cell survival,” Journal of Virology, vol. 83, no. 6, pp. 2491–2499, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Allam, S. G. Sayyed, O. P. Kulkarni, J. Lichtnekert, and H.-J. Anders, “Mdm2 promotes systemic lupus erythematosus and lupus nephritis,” Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2016–2027, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. E. M. Tan, A. S. Cohen, J. F. Fries et al., “The 1982 revised criteria for the classification of systemic lupus erythrematosus,” Arthritis and Rheumatism, vol. 25, no. 11, pp. 1271–1277, 1982. View at Publisher · View at Google Scholar · View at Scopus
  9. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee, “Preliminary criteria for the classification of systemic sclerosis (scleroderma),” Arthritis and Rheumatism, vol. 23, no. 5, pp. 581–590, 1980. View at Publisher · View at Google Scholar
  10. J.-Y. Zhang, R. Megliorino, X.-X. Peng, E. M. Tan, Y. Chen, and E. K. L. Chan, “Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma,” Journal of Hepatology, vol. 46, no. 1, pp. 107–114, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. Chen, Y. Zhou, S. Qiu et al., “Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma,” Cancer Letters, vol. 289, no. 1, pp. 32–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. H. Aldar, A. T. Lapa, B. Bellini et al., “Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus,” Lupus, vol. 21, no. 11, pp. 1225–1231, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Cahilly-Snyder, T. Yang-Feng, U. Francke, and D. L. George, “Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line,” Somatic Cell and Molecular Genetics, vol. 13, no. 3, pp. 235–244, 1987. View at Publisher · View at Google Scholar · View at Scopus
  14. S. S. Fakharzadeh, S. P. Trusko, and D. L. George, “Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line,” The EMBO Journal, vol. 10, no. 6, pp. 1565–1569, 1991. View at Google Scholar · View at Scopus
  15. M. Wade, Y. V. Wang, and G. M. Wahl, “The p53 orchestra: Mdm2 and Mdmx set the tone,” Trends in Cell Biology, vol. 20, no. 5, pp. 299–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Thomasova, S. R. Mulay, H. Bruns, and H.-J. Anders, “p53-independent roles of MDM2 in NF-κB signaling: implications for cancer therapy, wound healing, and autoimmune diseases,” Neoplasia, vol. 14, no. 12, pp. 1097–1101, 2012. View at Google Scholar · View at Scopus
  17. M. Wade, Y.-C. Li, and G. M. Wahl, “MDM2, MDMX and p53 in oncogenesis and cancer therapy,” Nature Reviews Cancer, vol. 13, no. 2, pp. 83–96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Mayr, D. Bund, M. Schlee et al., “MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes,” Experimental Hematology, vol. 34, no. 1, pp. 44–53, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. R. Chai, B. Peng, L. P. Dai, W. Qian, Y. Zhang, and J. Y. Zhang, “Autoantibodies response to MDM2 and p53 in the immunodiagnosis of esophageal squamous cell carcinoma,” Scandinavian Journal of Immunology, vol. 80, no. 5, pp. 362–368, 2014. View at Publisher · View at Google Scholar
  20. E. Šimelyte, S. Rosengren, D. L. Boyle, M. Corr, D. R. Green, and G. S. Firestein, “Regulation of arthritis by p53: critical role of adaptive immunity,” Arthritis & Rheumatism, vol. 52, no. 6, pp. 1876–1884, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Menendez, M. Shatz, and M. A. Resnick, “Interactions between the tumor suppressor p53 and immune responses,” Current Opinion in Oncology, vol. 25, no. 1, pp. 85–92, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S.-J. Zheng, S.-E. Lamhamedi-Cherradi, P. Wang, L. Xu, and Y. H. Chen, “Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function,” Diabetes, vol. 54, no. 5, pp. 1423–1428, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Herkel, A. Mimran, N. Erez et al., “Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies,” Journal of Autoimmunity, vol. 17, no. 1, pp. 63–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Sherer, A. Gorstein, M. J. Fritzler, and Y. Shoenfeld, “Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients,” Seminars in Arthritis and Rheumatism, vol. 34, no. 2, pp. 501–537, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Gasparini, A. Tommasini, and G. Zauli, “The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation,” Human Immunology, vol. 73, no. 4, pp. 342–345, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. S. R. Mulay, D. Thomasova, M. Ryu, and H.-J. Anders, “MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice,” Kidney International, vol. 81, no. 12, pp. 1199–1211, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Bernatsky, R. Ramsey-Goldman, and A. E. Clarke, “Malignancy in systemic lupus erythematosus: what have we learned?” Best Practice & Research: Clinical Rheumatology, vol. 23, no. 4, pp. 539–547, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Gayed, S. Bernatsky, R. Ramsey-Goldman, A. E. Clarke, and C. Gordon, “Lupus and cancer,” Lupus, vol. 18, no. 6, pp. 479–485, 2009. View at Publisher · View at Google Scholar · View at Scopus